early rosettes was not found when the lymphocytes of multiple sclerosis patients were exposed to extracts of control brains. In contrast the sensitised cells were found in the circulation in only two of 11 patients with multiple sclerosis in acute relapse. The percentage of circulating T-lymphocytes which formed early rosettes was lower in the group of patients suffering a relapse than in patients in remission. A longitudinal study of one patient who was tested before, during and after a relapse revealed the disappearance from the blood of the sensitised T-cells during the relapse and their subsequent reappearance after recovery. Of 36 patients with other neurological diseases, two responded solely to multiple sclerosis brain, two responded to both multiple sclerosis and control brain, and three responded only to control brain. No healthy controls showed sensitisation to any brain extract.
There is evidence to suggest that T-cell dependent cell mediated immunity may contribute to the pathogenesis of multiple sclerosis.' Offner et al,' using the test of enhancement of early rosettes, showed specific sensitisation of peripheral blood lymphocytes from multiple sclerosis patients to multiple sclerosis brain extracts. In view of the important implications for the pathogenesis and treatment of multiple sclerosis we attempted to reproduce their findings, extending the range of neurological controls, and examining the proportion of early rosette forming cells and the sensitisation at different stages in the course of the disease.
The marker of the human thymus-dependent (T) lymphocyte used is its ability to bind sheep red blood cells (SRBC) to the cell surface in the form of a rosette. A sub-population of T-cells has been identified with very high affinity for SRBC3; they are known variously as "active T-cells" or "early rosetting T-cells" because they form A longitudinal study in a 22 year old woman with multiple sclerosis shows that in the first test, when she had only minor symptoms of brain stem disorder, her T-lymphocytes showed a marked sensitivity to multiple sclerosis brain. When next seen, one month later, she had been unable to walk for a week with what was judged clinically to have been an episode of brain stem demyelination; the number of circulating early T-cells had dropped but the cells still showed sensitisation. Five days later her early T-cells had dropped to 10% and the sensitisation had disappeared. She gradually improved clinically over the next few weeks and ultimately made an excellent recovery. As can be seen from the figure it took over two months for the ERFC percentage to return to its former level and for sensitisation to return.
Discussion
Although there have been conflicting reports on changes in total circulating T-cells there is some Table 2 evidence that early T-cells are reduced in the blood of multiple sclerosis patients.8 9 We have found that reduction in the proportion of early T-cells is only significant during a relapse, thus agreeing with concurrent findings of Traugott et al. 8 Moreover during a relapse T-cells are not activated by added extract of MS brain. As shown by Offner and her colleagues,2 7 however, there is a significant increase in the early rosette forming T-cells when the extract is added to lymphocytes from multiple sclerosis patients in remission.
These observations are of particular interest for circulating T-lymphocytes have previously been shown to be sensitised to myelin basic protein8 1011 12 but the effect seems to be less specific than the uncharacterised antigen derived from the post nuclear supernatant of multiple sclerosis brain and the sensitisation is not so clearly related to the disease status of the patient. Recently Offner and colleagues13 have found lymphocytes of all multiple sclerosis patients, but none with other neurological diseases, responded to a partially purified fraction of multiple sclerosis brain.
In a preliminary longitudinal study (figure) we found that at the beginning of an attack there was a slow reduction in the proportion of active T-cells in the circulation and paralleling the relapse a loss of sensitivity to added multiple sclerosis brain antigen.
We consider that there is a striking resemblance between the changes in early T-cell populations during the course of multiple sclerosis and changes seen in guinea pigs with experimental allergic encephalomyelitis, a known cell-mediated demyelinating disease. Prior to the onset of clinical signs of experimental allergic encephalomyelitis there is a marked increase of circulating early Tcells'4 and a T-cell sensitivity to basic protein as revealed by enhancement of the early rosette test. 15 There follows an abrupt decrease when the animals develop clinical signs just before death, while circulating total T-cells and B-cells show little change.'4 Cells recovered from the meninges and surface of the spinal cord show a higher percentage of early rosette-forming cells than the peripheral blood of normal guinea pigs, suggesting that there has been a migration of early T-cells from the circulation into the CNS at the time of relapse. '; During a relapse it has been repeatedly observed that there is an increase in total T-cells in the CSF17 1819 although these may not be predominantly early rosetting T-cells.20
On the basis of our findings, therefore, it is rational to use immunosuppressant therapy against T-cells of the type already found to be successful in the treatment of experimental allergic encephalomyelitis. 
